This article, entitled “QGC606, a best-in-class orally active centrally acting aminopeptidase A inhibitor prodrug, for…
Home > Blog
Testimony of Denis, shareholder since 2016 (in French)
Testimony of Denis, shareholder since 2016 (in French) See the video
First patient enrolled in REFREH study
First patient enrolled in REFREH study Read the press realease
August 28th: Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure
August 28th: Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure…
Exclusive interview with Professor Gilles Montalescot
Exclusive interview with Professor Gilles Montalescot See the video
QUORUM study: Results Announcement next August 27, 2021 at 10:30 am CEST
QUORUM study: Results Announcement next August 27, 2021 at 10:30 am CEST Read the press…
Quantum Genomics Secures €3 Million Non-dilutive Financing
Quantum Genomics Secures €3 Million Non-dilutive Financing Read the press realease
Quantum Genomics will Present Top-line Results from its QUORUM study at European Society of Cardiology (ESC) Meeting
Quantum Genomics will Present Top-line Results from its QUORUM study European Society of Cardiology (ESC)…
Quantum Genomics Reports Full Year 2020 Operating and Financial Results
Quantum Genomics Reports Full Year 2020 Operating and Financial Results Read the press realease
Orient EuroPharma (OEP) acquires a stake in Quantum Genomics
As a follow-up to the agreement signed last September, OEP acquired a minority stake in…